Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.

Inclusion Criteria: * Male, over 19 years of age * Male participants must agree to use an adequate contraception method from the first to the third month after the last dose. * Participants must have a body mass index (BMI) between 18.5 and 30.0 kg/m2, inclusive(BMI = weight/height2), and body weight not less than 50 kg. * Subjects without congenital or chronic diseases within the last 3 years and without pathologic symptoms as determined by medical diagnosis. * Participants must be healthy on the basis of clinical laboratory tests performed at screening. * Informed of the investigational nature of this study and voluntarily agree to participate in this study. Exclusion Criteria: * Clinically significant medical or psychiatric illness. * Hypotension (SBP ≤ 90 mmHg or DBP ≤ 50 mmHg) or hypertension (SBP ≥ 150 mmHg or DBP ≥ 100 mmHg). * A marked baseline prolongation of QTc. * Within 14 days prior to the first administration of investigational product, use of prescription drugs or herbal medication, or within 7 days use of any over-the-counter medications * Participants who are planning COVID-19 vaccine within 14 days before the first intake of study drug and to the end of the trials.